JESSICA P HWANG to Antineoplastic Agents
This is a "connection" page, showing publications JESSICA P HWANG has written about Antineoplastic Agents.
Connection Strength
0.853
-
Cost-Effectiveness Analysis of Hepatitis B Virus Screening and Management in Patients With Hematologic or Solid Malignancies Anticipating Immunosuppressive Cancer Therapy. JCO Clin Cancer Inform. 2019 03; 3:1-12.
Score: 0.137
-
Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. Cancer. 2017 Sep 01; 123(17):3367-3376.
Score: 0.121
-
Reply to J. Cabezas et al. J Clin Oncol. 2016 Jan 20; 34(3):290-1.
Score: 0.110
-
Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Clin Oncol. 2015 Jul 01; 33(19):2212-20.
Score: 0.105
-
Hepatitis C virus screening in patients with cancer receiving chemotherapy. J Oncol Pract. 2014 May; 10(3):e167-74.
Score: 0.097
-
Hepatitis B virus management to prevent reactivation after chemotherapy: a review. Support Care Cancer. 2012 Nov; 20(11):2999-3008.
Score: 0.087
-
Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract. 2012 Jul; 8(4):e32-9.
Score: 0.086
-
Hepatitis B virus reactivation in patients with past HBV infection receiving anti-CD38 monoclonal antibodies. Hepatol Int. 2023 04; 17(2):509-511.
Score: 0.045
-
Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol. 2020 11 01; 38(31):3698-3715.
Score: 0.038
-
Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update. J Oncol Pract. 2015 Jul; 11(4):e487-9.
Score: 0.026